The government’s top infectious disease expert spoke Friday during a White House coronavirus briefing.
“This is a wake-up call to all of us,” says Fauci, noting government scientists will be working to keep pace with virus mutations.
The nature of viruses is to change in ways that promote their spread, Fauci says. The evolution of mutant versions means scientists need to be “nimble” and ready to make tweaks to vaccines. So far, the mutants haven’t overwhelmed the protective power of vaccines.
Fauci says its important to vaccinate as many people as quickly as possible to keep new mutations from developing.
THE VIRUS OUTBREAK:
Johnson & Johnson 1-dose shot prevents virus, but less than some others. WHO team visits Wuhan hospital that had early coronavirus patients. The EU publishes vaccine contract, price redacted. Dubai blamed by several countries for spreading the coronavirus abroad after the city welcomed New Year’s revelers. Tanzania’s president says God has eliminated COVID-19 in the country; his own church begs to differ. Philadelphia’s problematic vaccine rollout raises larger questions.
HERE’S WHAT ELSE IS HAPPENING:
BERLIN -- Regulators have authorized AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union, amid criticism the bloc is not moving fast enough to vaccinate its population.
The European Medicines Agency licensed the vaccine Friday to be used in people 18 and over, although concerns had been raised this week that not enough data exist to prove it works in older people.
The shot is the third COVID-19 vaccine given the greenlight by the European Medicines Agency, after those made by Pfizer and Moderna. Both were authorized for all adults.
WASHINGTON — The Biden Administration won’t need any new coronavirus vaccines approved by the FDA to fulfill its plan to purchase 200 million additional doses by the summer.
White House press secretary Jen Psaki says while it’s a “positive step” for additional vaccines to receive FDA approval, the Biden Administration will rely solely on Moderna and Pfizer for its new purchases.
Johnson & Johnson announced Friday its single-dose coronavirus vaccine was effective, though at a lower rate than the Moderna and Pfizer vaccines. The company is seeking emergency-use authorization from the FDA.
Psaki says the Biden administration would “rely on our health and medical experts to advise” on additional vaccines.
Suga, speaking at a virtual meeting of the World Economic Forum, says the Olympics would be a symbol of human victory over the pandemic. He pledged to get infections under control in Japan as soon as possible and achieve a “safe and secure” Olympics.
Olympic officials have repeatedly said the games will be held in July as planned after a one-year postponement, though various scenarios including the holding of events without spectators are being considered.
Suga has been criticized for delaying virus measures until daily cases surged to new highs in late December. He eventually declared a partial state of emergency in early January, issuing non-binding requests through Feb. 7 for people to avoid crowds or eating out in groups and for restaurants and bars to close early.
New coronavirus cases in Tokyo have dipped but experts say they haven’t slowed enough, indicating the emergency measures could be extended for several more weeks.
KYIV, Ukraine — The parliament of Ukraine has passed a law banning registration of the coronavirus vaccine developed by Russia.
The vaccine, called Sputnik V, has been registered for use in 11 countries as well as in Russia. The parliament on Friday approved registration for vaccines used in the United States, China, Japan and the European Union, among other countries, but specifically excluded vaccines developed by “the aggressor state.”
Ukraine’s relations with Russia plunged after the 2014 Russian annexation of Crimea and the continuing conflict in the country’s east with Russia-backed separatists. Ukraine’s underfunded medical system has been hit hard by the coronavirus. The country of 44 million has recorded more than 1.2 million infections and more than 22,000 confirmed deaths.
NEW BRUNSWICK, N.J. — Johnson & Johnson says its vaccine appears to protect against COVID-19 with just one shot.
It’s not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. Results released Friday show the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective against the most serious symptoms.
These are preliminary findings from a study of 44,000 volunteers that is ongoing. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.
After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press. When the vaccinated did become infected, they had a milder illness.
The vaccine worked better in the U.S. compared to South Africa, where it was up against a tougher, mutated virus. The company says it will file an application for emergency use soon in the U.S., and then abroad.
It expects to have some ready to ship as soon as authorities give the green light and supply 100 million doses to the U.S. by June.
BERLIN — Swiss pharmaceutical company Novartis says it has signed an agreement to help production of the Pfizer-BioNTech coronavirus vaccine.
Novartis says the initial agreement calls for it to take active ingredient from Germany’s BioNTech and fill it into vials at its plant in Stein, Switzerland. The vials would be sent back to BioNTech for distribution.
Novartis says the plan is for it to start production during the second quarter, with the initial shipment of finished vaccines expected in the third quarter.
Novartis’ announcement comes after another rival, French drugmaker Sanofi, said Wednesday it would help bottle and package the BioNTech-Pfizer vaccine at a plant in Frankfurt.
PARIS — Nearly two weeks after France extended its vaccine campaign to over-75-year-olds, elderly residents across Paris are flocking to vaccination centers amid concerns of a vaccine shortfall.
France is expecting less than a third of planned deliveries of the AstraZeneca vaccine this quarter – 4.6 million doses instead of 15.8 million, according to French officials.
Nurses at a medical center in Paris’ residential 15th district are currently administering between 80 and 100 shots a day – a number that could drop.
“Our goal here is to administer the second jab within the recommended timeframe,” said the center’s Chief Doctor François Teboul. “The likely consequence is we will have to push back a number of first vaccinations in the weeks to come.”
Delays or production problems for the Pfizer-BioNTech vaccine have caused concerns across the European Union.
WASHINGTON — The new director of the Centers for Disease Control says officials have “scaled up” their surveillance of new coronavirus variants in the United States.
CDC Director Rochelle Walensky told ABC’s “Good Morning America” that previously “there has not been a public health infrastructure” to track such variants. Also, there weren’t resources to do “mass sequencing” of the virus across the country. She noted the coronavirus aid plan pushed by the Biden Administration includes funds to improve such tracing.
However, Walensky says it was “concerning” the two South Carolina individuals who were diagnosed with the more virulent strain first identified in South Africa didn’t know each other or travel there, so the “presumption” is there’s “community spread of this strain.”
BRUSSELS — The European Union has made public a redacted version of the contract it agreed with the drugmaker AstraZeneca which lies at the heart of a major row over coronavirus vaccine deliveries.
The EU’s executive branch, the European Commission, published the text of the advance purchasing agreement Friday after consulting the British-Swedish company.
Details about the price of the vaccine were notably redacted. The U.K. is thought to be paying far more for the vaccine than the 27-nation bloc.
Earlier this week, the EU lashed out at the drugmaker after it said it would not be able to deliver the 80 million doses that it hoped to provide and could only supply 31 million.
The advance purchasing agreement was signed before any vaccine existed. European authorities are expected to approve the AstraZeneca vaccine later Friday, but questions remain over how effective it is among people over 65.
ROME — Italy’s virus czar says pharmaceutical company Moderna officially advised the government Friday that it would reduce a planned upcoming vaccine delivery to Italy by 20%, fueling increasing outrage in Italy as such delays have forced the country to drastically slow down its vaccine campaign.
Domenico Arcuri expressed “stupor, concern and discomfort” at Moderna’s decision, noting that it came after both Pfizer and AstraZeneca announced similar delays in scheduled deliveries. The Italian government has formally advised Pfizer it is weighing legal action.
Arcuri said Moderna told the government its Feb. 8 deliveries would be 132,000 doses instead of a planned 166,000.
The reduced deliveries have meant that Italy’s plan to start vaccinating Italians over age 80 on a mass scale have been delayed by several weeks, and reduced by more than half the number of shots administered each day. Italy concentrated the first weeks of its vaccine campaign on health care workers, with about 1 million of the 1.7 million doses administered so far going to doctors and nurses.
MADRID — Spain’s health minister says that between 5 and 10% of all confirmed coronavirus infections are believed to be derived from a mutation seen as responsible for the high contagion rates seen first in the United Kingdom and later in other countries.
Appearing Friday at a Congress of Deputies health commission, Carolina Darias said that so far confirmed cases of the new variant in Spain stand at 350 but that experts’ analysis showed that up to 10% of new infections could be attributed to it.
“The following weeks are crucial to see if this variant takes over ... like has happened in other countries,” Darias told lawmakers.
On Thursday Spain logged nearly 35,000 new cases of the virus and 515 confirmed deaths, although the 14-day rate of infection per 100,000 residents dropped slightly for the first time in nearly a month.
Authorities say that an abrupt decline would be needed for overwhelmed hospitals to free up space before any effects of the new variant increases contagion and hospitalizations again.
BELGRADE, Serbia — Serbia has received an additional 40,000 doses of the Sputnik V vaccine from Russia, further boosting its so far successful coronavirus vaccination campaign when compared with the rest of the Balkans.
While its neighbors have struggled to secure the shots, Serbia has embarked on one of the fastest vaccine rollouts in Europe with some 400,000 people getting jabs so far in the country of 7 million.
One million doses of Chinese Sinopharm vaccines arrived in Serbia earlier this month as well as thousands of doses of the Pfizer and Sputnik V shots.
Serbian officials say all the vaccine shipments which have arrived have been directly negotiated with either Russia and China, or with the Pfizer producers in the U.S. They say that so far no vaccines have been delivered by the global Covax system aimed at providing affordable shots to poor and middle-income countries.
Serbia is also negotiating the domestic production of the Russian Sputnik V vaccine. The Russian and Chinese vaccines have not been approved by the European Union drug regulators.
AMSTERDAM — The European Medicines Agency says no new side effects linked to the coronavirus vaccine made by BioNTech and Pfizer were identified in the regulator’s first safety update on COVID-19 vaccines.
In a statement published Friday, the European regulator said its expert committee assessed reports of people who died after getting the vaccine and said their review “did not suggest a safety concern.” Earlier this month, Norwegian officials amended their vaccination advice to say that doctors should assess frail and severely ill elderly people to decide if they should be immunized.
The EMA concluded that safety data collected on the Pfizer vaccine are “consistent with the known safety profile of the vaccine” and noted that severe allergic reactions are a known, rare side effect. It said the frequency of such allergic reactions was about 11 cases per million doses in the U.S. but that there was no comparable European estimate yet.
The EMA authorized the Pfizer vaccine on December 21 and granted it a conditional license; Pfizer and BioNTech must submit safety reports every month in line with a heightened monitoring process. The agency said “there are no recommended changes regarding the use of the vaccine.”
BUDAPEST, Hungary — Hungary’s prime minister says a deal to purchase Chinese coronavirus vaccines could be concluded as early as Friday, which would make Hungary the first country in the European Union to purchase a vaccine from China.
Prime Minister Viktor Orban said on public radio that his government is monitoring the use of a vaccine developed by Chinese state-owned company Sinopharm in neighboring Serbia, which became the first European country to administer the drug after it received 1 million doses earlier this month.
Hungary’s drug regulator has not yet approved the Sinopharm vaccine. But a decree ordered by the government on Thursday streamlined the approval procedure by allowing any vaccine that had been administered to at least 1 million people to be used in Hungary.
Orban said he would personally choose to be inoculated with the Sinopharm vaccine since he trusted it the most.
Hungary last week was the first EU member to approve the Russian Sputnik V vaccine, and has ordered doses to treat 1 million people over the next three months. Orban has been critical of the EU’s vaccine procurement program and insisted that countries that pursue their own vaccine agreements are faring better.